Company Performance - Bioventus (BVS) has returned 102.5% year-to-date, significantly outperforming the Medical sector, which has returned an average of -5% [3] - The Zacks Consensus Estimate for BVS' full-year earnings has increased by 2.5% over the past quarter, indicating improved analyst sentiment and earnings outlook [7] - Bioventus is part of the Medical - Drugs industry, which has an average return of -11.4% year-to-date, further highlighting BVS's strong performance [9] Industry Context - The Medical sector consists of 1020 individual stocks and is currently ranked 3 in the Zacks Sector Rank [6] - The Medical - Biomedical and Genetics industry, which includes Adagene Inc. Sponsored ADR, has returned -12.3% year-to-date and is ranked 64 out of 501 stocks [5] - Adagene Inc. Sponsored ADR has returned 6.1% year-to-date, indicating it has also outperformed its sector [8]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $139 million, representing a 15% increase compared to the prior year, marking the fourth consecutive quarter of double-digit organic revenue growth [16][8] - Adjusted EBITDA for the quarter was over $24 million, an increase of $2 million or 8% year-over-year, with year-to-date adjusted EBITDA up 21% compared to the prior year [16][13] - Adjusted gross margin was 75%, down 10 basis points from the previous year [16] Business Line Data and Key Metrics Changes - Surgical solutions revenue grew by 18%, driven by strong performance in both ultrasonics and bone graft substitutes [17] - Pain treatments revenue also increased by 18%, primarily due to the brand recognition and clinical differentiation of Durolane [17] - Restorative therapies sales grew by 6%, with Exogen showing accelerated growth [18] Market Data and Key Metrics Changes - The international segment experienced a 10% growth compared to the prior year, driven by Durolane and recovery of delayed shipments in the ultrasonics business [18] - The company is focused on expanding its market share in the $1 billion opportunity across spine, neuro, and general surgery [9] Company Strategy and Development Direction - The company aims to accelerate revenue growth, improve profitability, and enhance liquidity, with a commitment to expanding adjusted EBITDA margin by at least 100 basis points annually [13][14] - A divestiture of the advanced rehabilitation business for $25 million is expected to close by the end of the year or early next year, allowing the company to focus on its core portfolio [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum and achieving above-market revenue growth, margin expansion, and cash flow acceleration in the coming years [7] - The company anticipates a material acceleration in cash flow in 2025, driven by reduced one-time cash costs and improved operational efficiencies [14][20] Other Important Information - The company raised its full-year revenue guidance to a range of $562 million to $567 million, reflecting a $2.5 million increase in the midpoint compared to previous guidance [21] - Adjusted earnings per share guidance for the year was increased to between $0.40 and $0.42, a $0.02 increase from prior guidance [22] Q&A Session Summary Question: Clarification on 2024 guidance and growth rate - Management indicated that lower growth in Q4 is expected due to unfavorable comparisons from the previous year and slower growth in bone graft substitutes [25] Question: Expectations for pain business in Q4 - Management feels confident about the pain business continuing its momentum, with some price benefits expected in Q4 [28] Question: Growth disparity in 2025 - Management noted that while the start of 2025 may be softer due to temporary lag effects, they remain optimistic about overall momentum [33] Question: Competitor concerns in the HA business - Management expressed no concerns regarding competitors, citing strong clinical differentiation and a dedicated sales force as key advantages [39] Question: Expectations for international business - Management is optimistic about the growth potential of the international business, acknowledging foundational work is needed [41]

November 5, 2024 Innovations For Active Healing Third Quarter 2024 Financial Results Agenda and Speakers Rob Claypoole President and Chief Executive Officer Update on 2024 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q3 2024 Results Update to 2024 Financial Guidance Forward Looking Statements and Use of Estimates Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sect ...

分组1 - Bioventus reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, and an increase from $0.05 per share a year ago [1] - The company achieved revenues of $138.96 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 4.82%, and up from $120.79 million year-over-year [2] - Bioventus shares have increased approximately 160.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 19.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $147.53 million, and for the current fiscal year, it is $0.40 on revenues of $560.78 million [7] - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Exhibit 99.1 Bioventus Reports Third Quarter Financial Results • Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth • Q3 Gross Margin Expanded 200 bps • Q3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, ...

Core Insights - Bioventus Inc. reported a 15.0% increase in Q3 revenue, marking the fourth consecutive quarter of double-digit organic growth, driven by strong performance in Pain Treatments and Surgical Solutions [2][5] - The company achieved a gross margin expansion of 200 basis points and generated cash from operations of $10.3 million, an increase of $18.6 million compared to the previous year [1][3] - The net loss from continuing operations decreased to $5.4 million from $8.8 million in the prior-year period, with adjusted EBITDA rising 8.4% to $23.6 million [3][4] Financial Performance - Q3 2024 worldwide revenue reached $139.0 million, up from $120.8 million in Q3 2023, with notable growth in Pain Treatments (16.3%) and Surgical Solutions (18.6%) [2][5] - Adjusted EBITDA for the third quarter was $23.6 million, reflecting strong revenue growth compared to $21.7 million in the prior year [3][35] - The company reported a loss per share of $0.07, an improvement from a loss of $0.12 in the prior-year period [4][18] Revenue Breakdown - U.S. net sales totaled $122.9 million, a 15.7% increase year-over-year, with Pain Treatments contributing $56.3 million and Surgical Solutions $41.2 million [5][6] - International net sales amounted to $16.1 million, a 10.2% increase, with Pain Treatments growing by 29.3% [5][6] Strategic Developments - Bioventus is focused on executing strategic priorities to enhance revenue growth and profitability while reducing leverage to increase shareholder value [2][7] - The company has reached an agreement to divest its Advanced Rehabilitation Business for up to $45.0 million, expected to close by early 2025, which will help reduce debt and concentrate on core businesses [7][8] Future Guidance - For the twelve months ending December 31, 2024, Bioventus expects net sales between $562 million and $567 million, with adjusted EBITDA projected at $104 million to $107 million [8]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1024 companies in the Medical group. The Medical group currently sits ...

Bioventus (BVS) is expected to report third-quarter 2024 earnings next month. The Zacks Consensus Estimate for sales and earnings is pegged at $132.6 million and 6 cents per share, respectively.Estimates for Bioventus’ 2024 and 2025 earnings per share (EPS) have remained consistent in the past 60 days at 40 and 45 cents, respectively. The company delivered an earnings surprise of 171.43% in the last reported quarter. Image Source: Zacks Investment ResearchBVS’ Earnings Surprise HistoryThe company’s earnings ...

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0 ...

Shares of Bioventus (BVS) have surged 73% in the past three months, significantly outperforming the industry’s 1.3% growth. The stock has outperformed the sector and the S&P 500 during the same period. BVS' shares are also trading above the 50-day and 200-day moving averages.BVS Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis uptick in stock price was triggered by the company’s encouraging sales performance across its business segments, especially the Pain Treatments ...